insights_auto
Waarom is 4142 gedaald 6,62%?
Meer informatiechevron_right
4142:TPE
Adimmune Corp
NT$ 14,80
arrow_downward
-6,62%(-1,05) 1D
20 nov, 13:30:09 GMT+8 · TWD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 4142 genereren…
Openen
NT$ 15,75
Hoog
NT$ 15,75
Laag
NT$ 14,80
Beursw.
6,36 mld.
Gem. vol.
1,13 mln.
Volume
1,63 mln.
Koers/winst-verhouding
85,76
52 wk hoog
NT$ 21,50
52 wk laag
NT$ 14,80
WPA
NT$ 0,17
Uitstaande aandelen
235,29 mln.
Aantal medewerkers
564
Openen
NT$ 15,75
Hoog
NT$ 15,75
Laag
NT$ 14,80
Beursw.
6,36 mld.
Gem. vol.
1,13 mln.
Volume
1,63 mln.
Koers/winst-verhouding
85,76
52 wk hoog
NT$ 21,50
52 wk laag
NT$ 14,80
WPA
NT$ 0,17
Uitstaande aandelen
235,29 mln.
Aantal medewerkers
564
Nieuwsartikelen
Van webbronnen en nieuwspartners
Reuters
·
20 minuten geleden
SocGen sees S&P 500 ending 2027 at 8,500 on AI, earnings support
Traders Union
·
32 minuten geleden
Ryan Detrick: S&P 500 posts six-day losing streak, longest since April 2024
Bloomberg.com
·
50 minuten geleden
S&P 500 Faces Technical Make-or-Break Moment Below 7,200 Line
Barron's
·
1 uur geleden
S&P 500 Futures Decline in Premarket Trading; Lennar, Louisiana-Pacific Lag
Profiel
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Over Adimmune Corp